
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: HuaZhu Ke, et al.	:	
APPLICATION NO.: 09/736,051	:	Examiner: Louise N. Leary
FILING DATE: December 13, 2000	:	Group Art Unit: 1654
TITLE: Combination Therapy For Osteoporosis	:	

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. § 1.97 ET SEQ.

Applicant(s) herein make(s) available to the U.S. Patent and Trademark Office a copy of PTO-FB-A820 which lists the references cited by the applicant(s), copies of which are enclosed.

The Examiner is requested to consider carefully the complete text of these references in connection with the examination of the above-identified application in accord with 37 C.F.R. § 1.104(a). It is believed the Examiner will concur with applicant's belief that the subject matter presently claimed is neither anticipated nor rendered obvious by the foregoing references.

It is requested that the references listed on the attached form PTO-FB-A820 be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. § 1302.12).

Respectfully submitted,

Date: 2 November 2006
Pfizer Inc.
Patent Department, MS 8260-1611
Eastern Point Road
Groton, Connecticut 06340
(860) 715-6645

/ John A. Wichtowski /
John A. Wichtowski
Attorney for Applicant(s)
Reg. No. 48,032

INFORMATION DISCLOSURE CITATION <i>(Use several sheets if necessary)</i>				ATTY. DOCKET NO. PC9344B				SERIAL NO. 09/736,051						
				APPLICANT HuaZhu Ke, et al.										
				FILING DATE December 13, 2000				GROUP 1654						
U.S. PATENT DOCUMENTS														
EXAMINER INITIAL			DOCUMENT NUMBER						DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
FOREIGN PATENT DOCUMENTS														
			DOCUMENT NUMBER						DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
													YES	NO
OTHER DOCUMENTS <i>(Including Author, Title, Date, Pertinent Pages, Etc.)</i>														
			Cheng, et al., Journal of Shanghai Medical. "Combined use of tamoxifen and DL-15-methyl prostaglandin F2 for termination of early pregnancy", Vol. 17, pp. 378-381 (1990) XP008065947 (Abstract in English only)											
EXAMINER			DATE CONSIDERED											
<small>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</small>														

Conforms with FORM PTO-FB-A820

INFORMATION DISCLOSURE